MANUFACTURING VIRAL PARTICLES

TARGETED DNA INTEGRATION WITH LENTIVIRAL VECTORS AND USES THEREOF

SYNCITIN-1 FUSION PROTEINS AND USES THEREOF FOR CARGO DELIVERY INTO TARGET CELLS

COMPOSITIONS AND METHODS FOR USE IN IMMUNOTHERAPY

COMPOSITIONS AND METHODS FOR TREATING NEUROCOGNITIVE DISORDERS

LENTIVIRAL TRIPLEX DNA, AND VECTORS AND RECOMBINANT CELLS CONTAINING LENTIVIRAL TRIPLEX DNA

LENTIVIRAL TRIPLEX DNA, AND VECTORS AND RECOMBINANT CELLS CONTAINING LENTIVIRAL TRIPLEX DNA

Cell Lines

Methods and compositions relating to improved lentiviral vectors and their applications

Methods and compositions relating to improved lentiviral vectors and their applications

Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA

Immunogenic compositions comprising FIV and HIV gag antigens

Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA

Inhibition of human immunodeficiency virus integrase reaching dimer formation utilizing single-chain variable antibodies

Monoclonal antibodies to human immunodeficiency virus and uses thereof

Methods and compositions relating to improved lentiviral vectors and their applications

MATERIALS AND METHODS FOR DETECTING, PREVENTING, AND TREATING RETROVIRAL INFECTION

Detection of HIV-related proteins in urine

Detection of HIV-related proteins in urine

Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA

Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA

MONOCLONAL ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS AND USES THEREOF

METHOD FOR DETERMINING ONE OF THE TWO HUMAN IMMUNODEFICIENCY VIRUS (HIV) INTEGRASE ENZYMATIC ACTIVITIES

Antigen conjugates and uses thereof

Detection of HIV-related proteins in urine

Vector for expressing NC protein of HIV and method for producing NC protein using the same

Methods and compositions relating to improved lentiviral vectors and their applications

COMPOSITIONS AND METHODS FOR ELICITING AN IMMUNE RESPONSE TO ESCAPE MUTANTS OF TARGETED THERAPIES

Method for inducing cross-reactive immune responses to the human immunodeficiency virus (HIV) in a host by administering feline immunodeficiency virus (FIV) capsid (CA) or reverse transcriptase (RT) immunogens

VLP-antigen conjugates and their uses as vaccines

Inhibition of HIV replication and expression of p24 with eIF-5A

Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA

Methods of identifying optimal variants of peptide epitopes

Combinatorial selection of phosphorothioate aptamers for RNases

Methods of adenovirus production

Monoclonal antibodies that recognize a shared epitope between the human immunodeficiency virus type 1 (HIV-1) capsid (CA/p24) and the human immunodeficiency virus type 2 (HIV-2) capsid (CA/p26)

Monoclonal antibodies that recognize a shared epitope between the human immunodeficiency virus type 1 (HIV-1) capsid (CA/p24) and the human immunodeficiency virus type 2 (HIV-2) capsid (CA/p26)

Monoclonal antibodies that recognize a shared epitope between the human immunodeficiency virus type 1 (HIV-1) capsid (CA/p24) and the human immunodeficiency virus type 2 (HIV-2) capsid (CA/p26)

Monoclonal antibodies that recognize a shared epitope between the human immunodeficiency virus type 1 (HIV-1) capsid (CA/p24) and the human immunodeficiency virus type 2 (HIV-2) capsid (CA/p26).

Monoclonal antibodies that recognize a shared epitope between the human immunodeficiency virus type 1 (HIV-1) capsid (CA/p24) and the human immunodeficiency virus type 2 (HIV-2) capsid (CA/p26)

Monoclonal antibodies that recognize a shared epitope between the human immunodeficiency virus type 1 (HIV-1) capsid (CA/p24) and the human immunodeficiency virus type 2 (HIV-2) capsid (CA/p26)